e-Drug3D

2029

PACRITINIB

INN
PACRITINIB

cas 937272-79-2

CLASS

ANTINEOPLASTIC
TREATMENT OF MYELOFIBROSIS
JANUS ASSOCIATED KINASE 2 (JAK2) INHIBITOR
FMS-LIKE TYROSINE KINASE 3 (FLT3) INHIBITOR

ROUTE (list)

ORAL

ATC code

L01EJ03

PK parameters

Tmax 4.5 HOUR
VD 229 LITER
Cl 2.09 LITER / HOUR
PPB 98.8 PERCENT
t1/2 27.7 HOUR

Target

TARGET JAK2
FLT3

PDB
5LBZ (STRUCTURE OF THE HUMAN QUINONE REDUCTASE 2 (NQO2) IN COMPLEX WITH PACRITINIB)

Ligand code = 6T3 (link to the list of PDB complexes)

Download experimental 3D coordinates of 6T3 with added hydrogens

DrugCentral

Receptor-type tyrosine-protein kinase FLT3 UNIPROT P36888 FLT3

Tyrosine-protein kinase JAK2 UNIPROT O60674 JAK2

Download SDF file

14,19-Dioxa-5,7,27-triazatetracyclo[19.3.1.12,6.18,12]heptacosa-1(25),2,4,6(27),8,10,12(26),16,21,23-decaene, 11-[2-(1-pyrrolidinyl)ethoxy]-, (16E)- (ACI)

Formula:
C28H32N4O3

Calculated chemical properties:

MW 472.58
NB_atoms 35
XLogP 4.47
PSA 61.392
NB_HD 1
NB_HA 7
fsp3 0.36
Lipinski(0=no;1=yes) 1

FDA
NDA 208712 (label) INN (PACRITINIB CITRATE) VONJO (SOBI) APPROVAL= AP YEAR= 2022 NEWMOLECULARENTITY